JP2022116251A - バレリアン組成物及び関連方法 - Google Patents
バレリアン組成物及び関連方法 Download PDFInfo
- Publication number
- JP2022116251A JP2022116251A JP2022089010A JP2022089010A JP2022116251A JP 2022116251 A JP2022116251 A JP 2022116251A JP 2022089010 A JP2022089010 A JP 2022089010A JP 2022089010 A JP2022089010 A JP 2022089010A JP 2022116251 A JP2022116251 A JP 2022116251A
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- valerian
- pharmaceutical dosage
- release portion
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000126014 Valeriana officinalis Species 0.000 title claims abstract description 176
- 235000013832 Valeriana officinalis Nutrition 0.000 title claims abstract description 176
- 235000016788 valerian Nutrition 0.000 title claims abstract description 176
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 33
- 239000002552 dosage form Substances 0.000 claims abstract description 155
- 229920000642 polymer Polymers 0.000 claims abstract description 80
- 239000002535 acidifier Substances 0.000 claims abstract description 40
- 239000007787 solid Substances 0.000 claims abstract description 17
- 239000011159 matrix material Substances 0.000 claims description 52
- 238000013268 sustained release Methods 0.000 claims description 51
- 239000012730 sustained-release form Substances 0.000 claims description 51
- 239000002775 capsule Substances 0.000 claims description 16
- 230000002378 acidificating effect Effects 0.000 claims description 15
- 238000003860 storage Methods 0.000 claims description 15
- 239000008363 phosphate buffer Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000006186 oral dosage form Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000015556 catabolic process Effects 0.000 claims description 6
- 238000006731 degradation reaction Methods 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 54
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 53
- 229960003987 melatonin Drugs 0.000 description 53
- 239000000047 product Substances 0.000 description 39
- 239000004480 active ingredient Substances 0.000 description 27
- 230000000202 analgesic effect Effects 0.000 description 21
- 238000000576 coating method Methods 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 16
- 239000003826 tablet Substances 0.000 description 16
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 15
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 229940120668 salicin Drugs 0.000 description 15
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 15
- 239000011248 coating agent Substances 0.000 description 13
- 239000008187 granular material Substances 0.000 description 13
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 13
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 13
- 230000037406 food intake Effects 0.000 description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 10
- 241000124033 Salix Species 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 229960003943 hypromellose Drugs 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- FEBNTWHYQKGEIQ-SUKRRCERSA-N valerenic acid Chemical compound C[C@@H]1CC[C@@H](\C=C(/C)C(O)=O)C2=C(C)CC[C@H]12 FEBNTWHYQKGEIQ-SUKRRCERSA-N 0.000 description 7
- FUHPCDQQVWLRRY-UHFFFAOYSA-N valerenic acid Natural products CC1CCC(C=C(/C)C(=O)O)C2C1CC=C2C FUHPCDQQVWLRRY-UHFFFAOYSA-N 0.000 description 7
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- -1 monoterpene isovalerate esters Chemical class 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229940084038 salix alba bark extract Drugs 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 229940038779 valerian root extract Drugs 0.000 description 5
- 239000001192 valeriana officinalis l. rhizome/root Substances 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000932 sedative agent Substances 0.000 description 4
- 230000001624 sedative effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 239000006057 Non-nutritive feed additive Substances 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241001278097 Salix alba Species 0.000 description 3
- XJNQXTISSHEQKD-HIPMNCMDSA-N Valerenolic Acid Chemical compound C[C@@H]1CC[C@@H](C=C(C)C(O)=O)C2=C(C)C[C@@H](O)[C@H]12 XJNQXTISSHEQKD-HIPMNCMDSA-N 0.000 description 3
- XJNQXTISSHEQKD-UHFFFAOYSA-N Valerenolic acid Natural products CC1CCC(C=C(C)C(O)=O)C2=C(C)CC(O)C12 XJNQXTISSHEQKD-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 3
- 239000007894 caplet Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000007891 compressed tablet Substances 0.000 description 3
- 238000006114 decarboxylation reaction Methods 0.000 description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010525 oxidative degradation reaction Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 229940005605 valeric acid Drugs 0.000 description 3
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 3
- 229960000604 valproic acid Drugs 0.000 description 3
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 2
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- SKGURMFKEAFAGD-CSYZDTNESA-N C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=C(O)C=C1 SKGURMFKEAFAGD-CSYZDTNESA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000050051 Chelone glabra Species 0.000 description 2
- 229940121909 GABA receptor agonist Drugs 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 description 2
- 244000062730 Melissa officinalis Species 0.000 description 2
- 235000010654 Melissa officinalis Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 244000020191 Salix babylonica Species 0.000 description 2
- 235000002493 Salix babylonica Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- SANOUVWGPVYVAV-UHFFFAOYSA-N isovaleramide Chemical compound CC(C)CC(N)=O SANOUVWGPVYVAV-UHFFFAOYSA-N 0.000 description 2
- 229930013686 lignan Natural products 0.000 description 2
- 150000005692 lignans Chemical class 0.000 description 2
- 235000009408 lignans Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- VBBXZFLAYWAXSK-HYJCDKNOSA-N (e)-3-[(1r,4s,7r,7ar)-1-acetyloxy-3,7-dimethyl-2,4,5,6,7,7a-hexahydro-1h-inden-4-yl]-2-methylprop-2-enoic acid Chemical compound C[C@@H]1CC[C@@H](\C=C(/C)C(O)=O)C2=C(C)C[C@@H](OC(C)=O)[C@H]12 VBBXZFLAYWAXSK-HYJCDKNOSA-N 0.000 description 1
- BTHFVSCNWFBKPY-UHFFFAOYSA-N 1-ethenylpurine Chemical compound C=CN1C=NC2=NC=NC2=C1 BTHFVSCNWFBKPY-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- DIZRSLUNVNGBPA-UHFFFAOYSA-N Alloeremophilon Natural products O=C1C(C(C)=C)CC2(C)C(C)CCCC2=C1 DIZRSLUNVNGBPA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000017164 Chronobiology disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 239000003691 GABA modulator Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 240000003114 Salix fragilis Species 0.000 description 1
- 235000018975 Salix fragilis Nutrition 0.000 description 1
- 241001278079 Salix nigra Species 0.000 description 1
- 241001299682 Salix purpurea Species 0.000 description 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
- 240000005481 Salvia hispanica Species 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDVXJTYHXDVWQO-NWANDNLSSA-N Valeranone Chemical compound C1CCC(=O)[C@@]2(C)C[C@@H](C(C)C)CC[C@]21C HDVXJTYHXDVWQO-NWANDNLSSA-N 0.000 description 1
- RJZWGDPBGWGJNU-MTXIQXFFSA-N Valerenal Chemical compound C[C@@H]1CC[C@@H](\C=C(/C)C=O)C2=C(C)CC[C@H]12 RJZWGDPBGWGJNU-MTXIQXFFSA-N 0.000 description 1
- RJZWGDPBGWGJNU-OQDDGJPTSA-N Valerenal Natural products O=C/C(=C\[C@H]1C2=C(C)CC[C@@H]2[C@H](C)CC1)/C RJZWGDPBGWGJNU-OQDDGJPTSA-N 0.000 description 1
- 241000792914 Valeriana Species 0.000 description 1
- BDIAUFOIMFAIPU-KVJIRVJXSA-N Valtratum Chemical compound C([C@]12[C@@H]3C(C(=CO[C@H]3OC(=O)CC(C)C)COC(C)=O)=C[C@@H]1OC(=O)CC(C)C)O2 BDIAUFOIMFAIPU-KVJIRVJXSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
- VBBXZFLAYWAXSK-UHFFFAOYSA-N acetoxyvalerenic acid Natural products CC1CCC(C=C(C)C(O)=O)C2=C(C)CC(OC(C)=O)C12 VBBXZFLAYWAXSK-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229940095602 acidifiers Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- RKCHCKMAQPJXBM-UHFFFAOYSA-N ammonium isovalerate Chemical compound N.CC(C)CC(O)=O RKCHCKMAQPJXBM-UHFFFAOYSA-N 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000009477 fluid bed granulation Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000399 hydroalcoholic extract Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- QRVMFXFSGYDNJI-HVNMYJMUSA-N kessane Chemical class C1C[C@@]2(C)[C@@H]3CC[C@@H](C)[C@H]3C[C@@H]1C(C)(C)O2 QRVMFXFSGYDNJI-HVNMYJMUSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 description 1
- 235000007221 pinoresinol Nutrition 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 229940068146 valepotriate Drugs 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- HDVXJTYHXDVWQO-UHFFFAOYSA-N valeranone Natural products C1CCC(=O)C2(C)CC(C(C)C)CCC21C HDVXJTYHXDVWQO-UHFFFAOYSA-N 0.000 description 1
- 235000020767 valerian extract Nutrition 0.000 description 1
- 235000017468 valeriana Nutrition 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000001459 whitebark Nutrition 0.000 description 1
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Anesthesiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本願は、参照によりその全体が本明細書に組み込まれる、2016年5月6日に出願された米国仮出願第62/332,738号の優先権を主張する。
本願は、サプリメント組成物の分野、及びより詳細には、バレリアン(valerian、カノコソウ)組成物に関する。
本願には、EFS-web経由で米国特許商標庁に「Sequence_Listing.txt」というテキストファイルとして電子的に提出された配列表が含まれる。電子的に提出された配列表は、37CFR§1.821(c)により要求される書類、及び37CFR§1.821(c)により要求されるコンピュータ可読ファイルの両方として機能する。前記配列表に含まれる情報は、本明細書中にその全体が参考により組み込まれる。
バレリアン(Valeriana officianalis、セイヨウカノコソウ)は何世紀にもわたって薬草療法として使用されてきた植物である。その根抽出物は、鎮静剤、抗不安薬、筋肉弛緩剤、及び抗けいれん剤としての使用が提案されている。バレリアンの根(valerian root、吉草根)及びその抽出物は現在、栄養補助食品として入手可能である。
バレリアン含有医薬剤形組成物がここに記載されている。
バレリアン、ヒドロゲル形成ポリマー、ある量の酸性化剤、及び水を組み合わせることによって酸性化されたポリマーマトリックスを形成するステップと、
前記酸性化されたポリマーマトリックスを包含する固体医薬投与形態を作製するステップと、
を含む。酸性化剤の前記量は、薬学的投与形態が25℃及び相対湿度60%で保存された場合に、前記バレリアンの分解を防止することによって、前記固体医薬投与形態を安定にする。
本明細書で使用される用語「バレリアン」は、バレリアンの根、バレリアン抽出物、及び/又はバレリアンにおける治療的に活性な化合物、例えばバレレン酸などの、及び/又はバルトラート及びジドロバルトラートなどのバレポトリアートを包含する。バレリアンは、乾燥した根、粉末又は液体の形態であり得る。前記液体形態は、溶媒中に懸濁した前記バレリアンの根の活性成分を含有する。アルコールは、抽出溶媒として典型的に使用されるが、前記液体形態は油であってもよい。
表1: 前記バレリアン含有プロダクトの例における活性成分(複数可)の量。
この実施例では、前記バレリアンプロダクトは、2つの部分からなる投与形態として調製される。前記投与形態は、迅速放出部分及び徐放部分を包含する。前記バレリアンプロダクトの内容が表2において要約される。SRは、当該成分が前記徐放性部分(sustained release portion)の一部であることを示す。ERは、当該成分が前記迅速放出部分(expedited release portion)の一部であることを示す。
表2 投与形態の内容
前記迅速放出部分が、前記バレリアン根抽出物、PHARMACOAT(登録商標)615ヒプロメロース、及びクエン酸を包含する顆粒を包含することを除いて、この例におけるプロダクトは実施例1のものと同様である。このバレリアンプロダクトの内容が表3に要約される。
この実施例のプロダクトは、前記コアの上のゼラチンサブコートと、前記サブコートの上の仕上げコートとを有するバレリアン含有錠剤である。前記バレリアン及びクエン酸は、前記錠剤中の顆粒内にある。前記バレリアンプロダクトの内容が表5に要約される。
表5. 投与形態の内容
この例におけるプロダクトは、前記コアの上のゼラチンサブコートと、前記サブコートの上の仕上げコートとを有するバレリアン含有二層錠剤である。前記バレリアン及び前記クエン酸は、前記錠剤中の顆粒内にある。前記バレリアン及び前記クエン酸はまた、前記迅速放出層及び前記徐放性層の両方に存在する。前記バレリアンプロダクトの内容が表6に要約される。
表6. 投与形態の内容
Claims (32)
- その中にバレリアン及び酸性化剤の量が含まれるポリマーを包含するソリッドコアを有する治療上有効な医薬投与形態を含む組成物であって、酸性化剤の前記量は、前記ポリマーに2~5のpHを与えるのに十分である、組成物。
- 酸性化剤の前記量は、前記医薬投与形態が25℃及び相対湿度60%で保存された場合に前記バレリアンの分解を防止することによって、前記医薬投与形態の貯蔵を安定にする、請求項1に記載の組成物。
- 酸性化剤の前記量が、前記ポリマーに3~5のpHを付与するのに十分である、請求項1に記載の組成物。
- 前記医薬投与形態が、
前記医薬投与形態中の前記バレリアンの5%~50%を包含する迅速放出部分であって、前記迅速放出部分は、0.1N HCl溶液中に置いてから約2時間以内にその中の前記バレリアンを放出するのに有効である、迅速放出部分と;
前記医薬投与形態中の前記バレリアンの残部を包含する徐放性部分であって、前記徐放性部分は、6.8のpHを有するリン酸緩衝液中に置いてから約10時間以内にその中の前記バレリアンを放出するのに有効である、徐放性部分と;
包含する、請求項1に記載の組成物。 - 前記医薬投与形態が、錠剤、カプセル及び多粒子から選択される少なくとも1つの経口投与形態である、請求項1に記載の組成物。
- 前記ポリマーが、水の吸収時に膨潤するヒドロゲル形成ポリマーである、請求項1に記載の組成物。
- 前記医薬投与形態が、約150mg~約250mgのバレリアンを包含する、請求項1に記載の組成物。
- バレリアンは前記医薬投与形態の15%w/w~45%w/wであり;
前記酸性化剤は前記医薬投与形態の1%w/w~20%w/wであり;
前記ポリマーは前記医薬投与形態の1%w/w~15%w/wである;
請求項1に記載の組成物。 - 酸性化されたポリマーマトリックス内にバレリアンを包含するソリッドコアと、
前記バレリアンの第1の画分を包含する迅速放出部分であって、0.1N HCl溶液中に置いてから約2時間以内に前記第1の画分を放出するのに有効である、迅速放出部分と、
前記バレリアンの第2の画分を包含する徐放性部分であって、前記徐放性部分は、6.8のpHを有するリン酸緩衝液中に置いてから約10時間以内に前記第2の画分を放出するのに有効である、徐放性部分と、
を有する治療上有効な医薬投与形態を含む組成物。 - 前記バレリアンの前記第1の画分が、前記バレリアンの5%~50%であり、前記バレリアンの前記第2の画分が、前記医薬投与形態中のバレリアンの残部である、請求項9に記載の組成物。
- 前記酸性化されたポリマーマトリックスが2~5のpHを有する、請求項9に記載の組成物。
- 酸性化されたポリマーマトリックスが3~5のpHを有する、請求項9に記載の組成物。
- 前記酸性化されたポリマーマトリックスが、前記医薬投与形態が25℃及び相対湿度60%で保存された場合に、前記バレリアンの分解を防止することによって、前記医薬投与形態の貯蔵を安定にする、酸性化剤のバレリアン安定性向上量を包含する、請求項9に記載の組成物。
- 前記医薬投与形態が、錠剤、カプセル及び多粒子から選択される少なくとも1つの経口投与形態である、請求項9に記載の組成物。
- 前記酸性化されたポリマーマトリックスが、水の吸収時に膨潤するヒドロゲル形成ポリマーである、請求項9に記載の組成物。
- 前記医薬投与形態が、約150mg~約250mgのバレリアンを包含する、請求項9に記載の組成物。
- バレリアンは前記医薬投与形態の15%w/w~45%w/wであり;
前記酸性化されたポリマーマトリックス中の酸性化剤は前記医薬投与形態の1%w/w~20%w/wであり;
前記酸性化されたポリマーマトリックスのポリマーは前記医薬投与形態の1%w/w~15%w/wである;
請求項9に記載の組成物。 - 貯蔵安定性バレリアン医薬投与形態を製造する方法であって、当該方法は、
バレリアン、ヒドロゲル形成ポリマー、ある量の酸性化剤、及び水を組み合わせることによって酸性化されたポリマーマトリックスを形成するステップと、
前記酸性化されたポリマーマトリックスを包含する固体医薬投与形態を作製するステップと、
を含み、
酸性化剤の前記量は、薬学的投与形態が25℃及び相対湿度60%で保存された場合に、前記バレリアンの分解を防止することによって、前記固体医薬投与形態を安定にする、
貯蔵安定性バレリアン医薬投与形態を製造する方法。 - 酸性化剤の前記量が、前記酸性化されたポリマーマトリックスに1~5のpHを付与するのに十分である、請求項18に記載の貯蔵安定性バレリアン医薬投与形態を製造する方法。
- 酸性化剤の前記量が、前記酸性化されたポリマーマトリックスに2~5のpHを付与するのに十分である、請求項18に記載の貯蔵安定性バレリアン医薬投与形態を製造する方法。
- 前記医薬投与形態が、
前記医薬投与形態中の前記バレリアンの5%~50%を包含する迅速放出部分であって、前記迅速放出部分は、0.1N HCl溶液中に置いてから約2時間以内にその中の前記バレリアンを放出するのに有効である、迅速放出部分と;
前記医薬投与形態中の前記バレリアンの残部を包含する徐放性部分であって、前記徐放性部分は、6.8のpHを有するリン酸緩衝液中に置いてから約10時間以内にその中の前記バレリアンを放出するのに有効である、徐放性部分と;
包含する、請求項18に記載の貯蔵安定性バレリアン医薬投与形態を製造する方法。 - 前記医薬投与形態が、錠剤、カプセル及び多粒子から選択される少なくとも1つの経口投与形態である、請求項18に記載の貯蔵安定性バレリアン医薬投与形態を製造する方法。
- バレリアンは前記医薬投与形態の15%w/w~45%w/wであり;
前記酸性化剤は前記医薬投与形態の1%w/w~20%w/wであり;
前記ポリマーは前記医薬投与形態の1%w/w~15%w/wである;
請求項18に記載の貯蔵安定性バレリアン医薬投与形態を製造する方法。 - それを必要とする患者に、その中にバレリアン及び酸性化剤の量が含まれるポリマーを包含するソリッドコアを有する医薬投与形態の治療上有効量を投与することを含む治療方法であって、酸性化剤の前記量は、前記ポリマーに2~5のpHを与えるのに十分である、治療方法。
- 投与が経口で行なわれる、請求項24に記載の治療方法。
- 酸性化剤の前記量は、前記医薬投与形態が25℃及び相対湿度60%で保存された場合に前記バレリアンの分解を防止することによって、前記医薬投与形態の貯蔵を安定にする、請求項24に記載の治療方法。
- 酸性化剤の前記量が、前記ポリマーに3~5のpHを付与するのに十分である、請求項24に記載の治療方法。
- 前記医薬投与形態が、
前記医薬投与形態中の前記バレリアンの5%~50%を包含する迅速放出部分であって、前記迅速放出部分は、0.1N HCl溶液中に置いてから約2時間以内にその中の前記バレリアンを放出するのに有効である、迅速放出部分と;
前記医薬投与形態中の前記バレリアンの残部を包含する徐放性部分であって、前記徐放性部分は、6.8のpHを有するリン酸緩衝液中に置いてから約10時間以内にその中の前記バレリアンを放出するのに有効である、徐放性部分と;
包含する、請求項24に記載の治療方法。 - 前記医薬投与形態が、錠剤、カプセル及び多粒子から選択される少なくとも1つの経口投与形態である、請求項24に記載の治療方法。
- 前記ポリマーが、水の吸収時に膨潤するヒドロゲル形成ポリマーである、請求項24に記載の治療方法。
- 前記医薬投与形態が、約150mg~約250mgのバレリアンを包含する、請求項24に記載の治療方法。
- バレリアンは前記医薬投与形態の15%w/w~45%w/wであり;
前記酸性化剤は前記医薬投与形態の1%w/w~20%w/wであり;
前記ポリマーは前記医薬投与形態の1%w/w~15%w/wである;
請求項24に記載の治療方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662332728P | 2016-05-06 | 2016-05-06 | |
US62/332,728 | 2016-05-06 | ||
JP2018558279A JP2019514977A (ja) | 2016-05-06 | 2017-05-04 | バレリアン組成物及び関連方法 |
PCT/US2017/031046 WO2017192843A1 (en) | 2016-05-06 | 2017-05-04 | Valerian composition and related methods |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018558279A Division JP2019514977A (ja) | 2016-05-06 | 2017-05-04 | バレリアン組成物及び関連方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022116251A true JP2022116251A (ja) | 2022-08-09 |
Family
ID=60203773
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018558279A Pending JP2019514977A (ja) | 2016-05-06 | 2017-05-04 | バレリアン組成物及び関連方法 |
JP2022089010A Pending JP2022116251A (ja) | 2016-05-06 | 2022-05-31 | バレリアン組成物及び関連方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018558279A Pending JP2019514977A (ja) | 2016-05-06 | 2017-05-04 | バレリアン組成物及び関連方法 |
Country Status (11)
Country | Link |
---|---|
US (4) | US10342873B2 (ja) |
EP (1) | EP3452020A4 (ja) |
JP (2) | JP2019514977A (ja) |
KR (1) | KR20190008265A (ja) |
CN (2) | CN117482062A (ja) |
AU (1) | AU2017260019A1 (ja) |
BR (1) | BR112018072795A2 (ja) |
CA (1) | CA3023305A1 (ja) |
MX (1) | MX2018013569A (ja) |
RU (1) | RU2018142019A (ja) |
WO (1) | WO2017192843A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024003704A1 (en) * | 2022-06-27 | 2024-01-04 | S.I.I.T. s.r.l. - SERVIZIO INTERNAZIONALE IMBALLAGGI TERMOSALDANTI | Multilayer tablet with differentiated release of melatonin and active ingredients |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2699075A1 (fr) * | 1992-12-11 | 1994-06-17 | Rech Sarl Ab | Préparation médicinale à libération programmable dans le temps notamment à base de plantes. |
JP2005516944A (ja) * | 2001-12-20 | 2005-06-09 | アルペックス ファーマ ソシエテ アノニム | 微粒子組成物 |
JP2009527504A (ja) * | 2006-02-23 | 2009-07-30 | イオメディックス スリープ インターナショナル エスアールエル | 良質な睡眠の誘導および維持のための組成物および方法 |
US20090197974A1 (en) * | 2008-02-05 | 2009-08-06 | Khaleeq Ahmed | Natural dietary supplement tablet |
CN102247443A (zh) * | 2010-12-23 | 2011-11-23 | 祝凤仪 | 治疗神经衰弱中药外洗粉、泡腾片的配方及其制备方法 |
US20120195968A1 (en) * | 2011-01-28 | 2012-08-02 | Shah Syed M | Controlled-release melatonin compositions and related methods |
JP2013053144A (ja) * | 2011-08-09 | 2013-03-21 | Daiichi Sankyo Healthcare Co Ltd | 鎮静剤組成物 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2713636B1 (fr) | 1993-12-07 | 1996-01-05 | Adir | Nouveaux dérivés naphtaléniques, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent. |
FR2727315A1 (fr) | 1994-11-30 | 1996-05-31 | Cooperative Agricole Laitiere | Utilisation d'un decapeptide a activite de type benzodiazepine pour la preparation de medicaments et de complements alimentaires |
US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
US6034239A (en) | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
US5856529A (en) | 1996-12-10 | 1999-01-05 | Bristol-Myers Squibb Company | Benzofuran and dihydrobenzofuran melatonergic agents |
IL147333A0 (en) | 1999-07-21 | 2002-08-14 | Ancile Pharmaceuticals | Process for the extraction of valerian root |
US6419956B1 (en) * | 1999-12-30 | 2002-07-16 | Ancile Pharmaceuticals | Odor-masking coating for a pharmaceutical preparation |
US20050129783A1 (en) | 2001-04-19 | 2005-06-16 | Mccleary Edward L. | Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health |
US8852656B2 (en) * | 2004-04-06 | 2014-10-07 | Taiyokagaku Co., Ltd. | Sleep improvement composition |
CA2566793C (en) | 2004-05-11 | 2013-07-16 | Egalet A/S | A novel dosage form |
WO2006137443A1 (ja) | 2005-06-22 | 2006-12-28 | Takeda Pharmaceutical Company Limited | 難溶性の有効成分を含有する錠剤 |
CN1850212A (zh) * | 2006-02-28 | 2006-10-25 | 潮州市强基制药厂 | 一种缬草油液体硬胶囊及其制备方法 |
ES2452342T3 (es) | 2006-09-27 | 2014-04-01 | Finzelberg Gmbh & Co. Kg | Preparación de extracto de valeriana |
US20080248106A1 (en) | 2007-04-05 | 2008-10-09 | Marvin Heuer | Melatonin-based composition for improved sleep |
EP2389350A1 (en) | 2009-01-23 | 2011-11-30 | Valericon GmbH | Methods for making valerenic acid derivatives and their use |
US20110064712A1 (en) | 2009-09-16 | 2011-03-17 | Daniel Moses Amato | Dietary Supplement Compositions and Methods of Making and Using the Same |
CN102370833B (zh) * | 2010-08-17 | 2014-03-26 | 北京亚东生物制药有限公司 | 一种解表祛暑的泡腾剂及其制备方法和用途 |
CN102058630B (zh) * | 2010-12-16 | 2014-03-19 | 苏州大学 | 一种镇静安神的缬草制剂及其制备方法 |
EA201391053A1 (ru) | 2011-01-17 | 2013-12-30 | Такеда Фармасьютикал Компани Лимитед | Таблетка, диспергируемая в ротовой полости |
CN102114060B (zh) * | 2011-02-22 | 2012-12-12 | 都晓伟 | 黑水缬草提取物及其制备方法和应用 |
US20130116215A1 (en) | 2011-10-28 | 2013-05-09 | Mireia Coma | Combination therapies for treating neurological disorders |
JP2015509708A (ja) | 2012-01-26 | 2015-04-02 | ウィキフーズ,インコーポレイテッド | 材料の天然輸送系内への封入 |
SI2806863T1 (sl) | 2012-01-26 | 2017-12-29 | Vanda Pharmaceuticals Inc. | Zdravljenje motenj cirkadianega ritma |
WO2014083438A2 (en) | 2012-11-09 | 2014-06-05 | Abattis Bioceuticals Corp | Nitric oxide increasing nutritional supplements and methods |
US20140271890A1 (en) | 2013-03-14 | 2014-09-18 | Thaer Ahmad | Controlled-release pharmaceutical composition |
MX2015014915A (es) | 2013-04-23 | 2016-03-07 | Zx Pharma Llc | Composicion multiparticulada con recubrimiento enterico que tiene un subrecubrimiento proteinico. |
PL231923B1 (pl) | 2013-10-28 | 2019-04-30 | Proteon Pharmaceuticals Spolka Akcyjna | Sposób enkapsulacji materiału zawierającego bakteriofagi, otrzymywana nim mikrokapsułka oraz jej zastosowania |
RU2535020C1 (ru) | 2014-01-23 | 2014-12-10 | Карпов Алексей Николаевич | Фармацевтическая композиция седативного и спазмолитического действия |
EP3102189B1 (en) * | 2014-02-06 | 2019-09-04 | Lan Bo Chen | Composition and method for aiding sleep |
MX2016014405A (es) * | 2014-05-05 | 2017-01-20 | Boehringer Ingelheim Int | Granulado de disolucion rapida. |
EP2974733B1 (de) | 2014-07-14 | 2016-09-07 | Dr. Willmar Schwabe GmbH & Co. KG | Kombination von Baldrianwurzelextrakt und Lavendelöl zur Verwendung zur Behandlung von Schlafstörungen |
-
2017
- 2017-05-04 AU AU2017260019A patent/AU2017260019A1/en not_active Abandoned
- 2017-05-04 EP EP17793336.3A patent/EP3452020A4/en active Pending
- 2017-05-04 JP JP2018558279A patent/JP2019514977A/ja active Pending
- 2017-05-04 RU RU2018142019A patent/RU2018142019A/ru not_active Application Discontinuation
- 2017-05-04 CN CN202311459688.5A patent/CN117482062A/zh active Pending
- 2017-05-04 CA CA3023305A patent/CA3023305A1/en active Pending
- 2017-05-04 BR BR112018072795-4A patent/BR112018072795A2/pt active Search and Examination
- 2017-05-04 WO PCT/US2017/031046 patent/WO2017192843A1/en active Application Filing
- 2017-05-04 US US15/586,709 patent/US10342873B2/en active Active
- 2017-05-04 MX MX2018013569A patent/MX2018013569A/es unknown
- 2017-05-04 CN CN201780027996.7A patent/CN109310638A/zh active Pending
- 2017-05-04 KR KR1020187035039A patent/KR20190008265A/ko not_active Application Discontinuation
-
2019
- 2019-07-03 US US16/502,976 patent/US11141484B2/en active Active
- 2019-07-09 US US16/506,443 patent/US11141485B2/en active Active
-
2021
- 2021-09-08 US US17/469,458 patent/US11701425B2/en active Active
-
2022
- 2022-05-31 JP JP2022089010A patent/JP2022116251A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2699075A1 (fr) * | 1992-12-11 | 1994-06-17 | Rech Sarl Ab | Préparation médicinale à libération programmable dans le temps notamment à base de plantes. |
JP2005516944A (ja) * | 2001-12-20 | 2005-06-09 | アルペックス ファーマ ソシエテ アノニム | 微粒子組成物 |
JP2009527504A (ja) * | 2006-02-23 | 2009-07-30 | イオメディックス スリープ インターナショナル エスアールエル | 良質な睡眠の誘導および維持のための組成物および方法 |
US20090197974A1 (en) * | 2008-02-05 | 2009-08-06 | Khaleeq Ahmed | Natural dietary supplement tablet |
CN102247443A (zh) * | 2010-12-23 | 2011-11-23 | 祝凤仪 | 治疗神经衰弱中药外洗粉、泡腾片的配方及其制备方法 |
US20120195968A1 (en) * | 2011-01-28 | 2012-08-02 | Shah Syed M | Controlled-release melatonin compositions and related methods |
JP2013053144A (ja) * | 2011-08-09 | 2013-03-21 | Daiichi Sankyo Healthcare Co Ltd | 鎮静剤組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP3452020A4 (en) | 2020-02-19 |
US10342873B2 (en) | 2019-07-09 |
CN117482062A (zh) | 2024-02-02 |
US20190328881A1 (en) | 2019-10-31 |
RU2018142019A (ru) | 2020-06-08 |
WO2017192843A1 (en) | 2017-11-09 |
US11141484B2 (en) | 2021-10-12 |
US20170319697A1 (en) | 2017-11-09 |
EP3452020A1 (en) | 2019-03-13 |
US11141485B2 (en) | 2021-10-12 |
AU2017260019A1 (en) | 2018-11-22 |
KR20190008265A (ko) | 2019-01-23 |
JP2019514977A (ja) | 2019-06-06 |
RU2018142019A3 (ja) | 2020-09-16 |
MX2018013569A (es) | 2019-03-14 |
US20190321475A1 (en) | 2019-10-24 |
US11701425B2 (en) | 2023-07-18 |
US20210401990A1 (en) | 2021-12-30 |
CA3023305A1 (en) | 2017-11-09 |
BR112018072795A2 (pt) | 2019-04-30 |
CN109310638A (zh) | 2019-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10888522B2 (en) | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients | |
US9474721B2 (en) | Abuse-resistant formulations | |
JP2015147812A (ja) | 口腔内崩壊錠の製造方法 | |
EP0749308B1 (en) | Film coated tablet of paracetamol and domperidone | |
JP2022534159A (ja) | 微細化した固形メラトニン組成物 | |
JP2022116251A (ja) | バレリアン組成物及び関連方法 | |
JPWO2007010930A1 (ja) | 口腔内崩壊製剤用の薬物含有被覆微粒子及びその製造方法 | |
JP2019532960A (ja) | エソメプラゾール含有複合カプセル剤及びその製造方法 | |
JP5718937B2 (ja) | パーキンソン病を治療するための医薬組成物及びその調製方法 | |
KR102568681B1 (ko) | 네포팜을 포함하는 경구 붕해 약학 조성물 및 그 제조 방법 | |
CA2648495C (en) | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix | |
TWI651084B (zh) | 包含異菸鹼醯胺(isoniazid)顆粒及利福噴丁(rifapentine)顆粒之包衣錠劑型態的抗肺結核穩定醫藥組合物及其製備方法 | |
US9155704B1 (en) | More palatable, bioequivalent pharmaceutical composition of carprofen | |
KR20160105662A (ko) | 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물 | |
JP2024074793A (ja) | 医薬組成物 | |
WO2023089553A1 (en) | Controlled release formulations of flavoxate and process for preparation thereof | |
WO2017115745A1 (ja) | 圧縮成型製剤 | |
TW201626990A (zh) | 含有褪黑激素和舍曲林的口服複合錠劑 | |
AU2004202902A1 (en) | Pharmaceutical composition comprising skim milk powder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220629 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220629 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230711 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231010 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240402 |